TTrialPathMatch Me to Trials
← Back to trials
RecruitingWeight Loss

Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)

Eligible age

18+ yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.

Sponsor: Viking Therapeutics, Inc.

You may qualify if…

  • ✓ 1. Age ≥18 years of age at the time of signing the informed consent.
  • ✓ 2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated).
  • ✓ Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
  • ✓ Cardiovascular disease includes, for example, ischemic cardiovascular disease, NYHA Functional Class I-III heart failure.
  • ✓ BMI calculated at the screening visit will be used to determine eligibility.

You may not qualify if…

  • ✕ 1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
  • ✕ 2. Self-reported body weight change of 5% or more within 3 months of screening
  • ✕ 3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (excluding liposuction or abdominoplasty if performed \>1 year prior to screening)
  • ✕ 4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
  • ✕ 5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes). If a participant has had gestational diabetes, they are allowed to be enrolled as long as the glycemic status has returned to normal levels after 12 months of completion of pregnancy
  • ✕ 6. Treatment with glucose-lowering agent(s) within 90 days before screening
  • ✕ 7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  • ✕ 8. History of acute or chronic pancreatitis

Where it's recruiting

Arizona

Tucson

California

Chula Vista · Lake Forest

Florida

Melbourne · The Villages

Georgia

Atlanta

Indiana

Evansville · Valparaiso

Kentucky

Louisville

Minnesota

Richfield

Missouri

Springfield

New York

Rochester

North Carolina

Morehead City

Oregon

Medford

Source: ClinicalTrials.gov · NCT07868835 · last updated 2026-11-16

Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) · TrialPath